Clinical Trials Logo

ALL Ph Positive clinical trials

View clinical trials related to ALL Ph Positive.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT01361438 Active, not recruiting - ALL Ph Positive Clinical Trials

De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients

LAL1509
Start date: June 2011
Phase: Phase 2
Study type: Interventional

This study will enroll adult de novo Ph+ acute lymphoblastic leukemia (ALL) patients (≥18 years, ≤60 years). Induction treatment will consist of 12 weeks of Dasatinib oral administration (140 mg QD). Patients will initiate treatment with steroids 7 days prior to starting Dasatinib and will continue up to day 31. Patients will continue treatment with Dasatinib up to day 84, except for disease progression, intolerable toxicity, or withdrawal from study.